Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma.

British journal of haematology - 1 Mar 2015

Varga Gergely, Mikala Gábor, Andrikovics Hajnalka, Koszarska Magdalena, Balassa Katalin, Ádám Emma, Kozma András, Tordai Attila, Masszi Tamás

Abstract excerpt

Nuclear factor kappa B (NFKB) plays an important role in multiple myeloma (MM), and bortezomib affects this pathway. We retrospectively analysed the effect of the NFKB1 -94ins/delATTG polymorphism on the survival of 295 MM patients treated at a single centre. The median progression-free survival (PFS) was 790 (659-921) d in patients with NFKB1 homozygous insertion genotype (I/I, n = 99) and 624 (515-733) d in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Boronic Acids
Share to Bortezomib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Multiple Myeloma

Share to NF-kappa B p50 Subunit

Share to Pyrazines

Share to Sequence Deletion

Share to Survival Rate

Source

Identifiers

PMID: 25363231
DOI: 10.1111/bjh.13197

Genes

NFKB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma.PMID 25363231Read ↗

Polymorphisms within genes encoding Ikaros family proteins IKZF1 and IKZF3 in multiple myeloma patients treated with thalidomide.Semantic proximity Read ↗

Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.Semantic proximity Read ↗

Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.Semantic proximity Read ↗

ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple MyelomaSemantic proximity Read ↗

A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support.Semantic proximity Read ↗

The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma.Semantic proximity Read ↗

CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.Semantic proximity Read ↗

Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.Semantic proximity Read ↗

A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma.Semantic proximity Read ↗

Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma.Semantic proximity Read ↗

Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.Semantic proximity Read ↗

The Association of GSTT1, GSTM1, and TNF-α Polymorphisms With the Risk and Outcome in Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.